<DOC>
	<DOCNO>NCT01058512</DOCNO>
	<brief_summary>The purpose research study find effect investigational drug NOV-205 level hepatitis C virus blood whether NOV-205 well-tolerated different dos take subject hepatitis C .</brief_summary>
	<brief_title>A Trial NOV-205 Hepatitis C Patients Who Failed Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>A serum HCV RNA level &gt; 100,000 IU/ml use quantitative , branchedchainDNA ( bDNA ) base assay ( low limit quantitation = ~650 IU/ml ) equally sensitive quantitative method . Infection genotype 1 HCV Documented failure respond treatment ( defined patient achieve early viral response ( EVR ) ( â‰¥2 log reduction serum HCV RNA undetectable HCV RNA 12 week treatment ) OR serum HCV RNA positive 24 week treatment pegylated interferon plus ribavirin hepatitis C Adequate laboratory parameter Women childbearing potential willing use two acceptable method birth control trial participation sterile postmenopausal ( define menstrual cycle great two year ) Sexually active male subject practice acceptable method contraception trial participation Have ability understand requirement trial , provide write informed consent , agree abide trial restriction return require assessment The subject must able self administer daily subcutaneous injection caregiver must able administer daily subcutaneous injection Clinical , laboratory , histological evidence liver cirrhosis Evidence hepatic decompensation ( presence history ascites , hepatic encephalopathy , variceal bleeding , hepatocellular carcinoma ) Coinfection human immunodeficiency virus ( HIV ) active hepatitis B virus ( HBV ) ( determine presence hepatitis B surface antigen ( HBsAg ) Have receive pegylated interferon and/or ribavirin within 60 day prior enrollment Any known preexist medical condition could interfere subject 's participation completion protocol Pregnant female nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>chronic HCV</keyword>
	<keyword>viral HCV</keyword>
	<keyword>genotype 1</keyword>
	<keyword>fail treatment pegylated interferon plus ribavirin</keyword>
</DOC>